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Abstract
We investigated the functional interaction between neuropeptide Y (NPY) receptors using nerve terminals and cultured rat hippo-
campal neurons, and we evaluated the involvement of voltage-gated Ca2+ channels (VGCCs) in NPY receptors-induced inhibition
of Ca2+ influx and glutamate release. The KCl-evoked release of glutamate from hippocampal synaptosomes was inhibited by 1
µM NPY and this effect was insensitive to either BIBP3226 (Y1 receptor antagonist) or L-152,804 (Y5 receptor antagonist), but
was sensitive to BIIE0246 (Y2 receptor antagonist). We could also pharmacologically dissect the NPY receptors activity by using
Y1, Y2 and Y5 receptor agonists ([Leu31,Pro34]NPY, NPY13-36, NPY (19-23)-(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-pancreatic
polypeptide (PP), respectively), and in all the cases we observed that these agonists could inhibited the KCl-induced release of
glutamate. However, the selective and specific co-activation of both Y1 and Y2 or Y2 and Y5 receptors resulted in non-additive
inhibition, and this effect was prevented in the presence of the Y2 antagonist, but was insensitive to the Y1 or Y5 receptor antagonist.
Moreover, as we previously showed for Y1 receptors, we also observed that the activation of Y5 receptors inhibited the glutamate
release in the dentate gyrus and CA3 subregion, without significant effect in the CA1 subregion of the hippocampus. The same
qualitative results were obtained when we investigated the role of NPY Y1 and Y2 receptors in modulating the changes in [Ca2+]i
due to KCl depolarisation in cultured hippocampal neurons. The inhibitory effect of nitrendipine (L-type VGCC blocker) or ω-
conotoxin GVIA (ω-CgTx; N-type VGCC blocker) was not potentiated by the simultaneous activation of Y1 or Y2 receptors.
Moreover, the exocytotic release of glutamate was inhibited by ω-agatoxin IVA (ω-Aga; P-/Q-type VGCC blocker), and this VGCC
blocker did not potentiate Y1, Y2 or Y5 receptor-mediated inhibition of glutamate release. Also, the effect of ionomycin in inducing
the exocytotic release of glutamate from hippocampal synaptosomes was insensitive to the activation of NPY receptors. In the
present paper, we identified a role for NPY Y1, Y2 and Y5 receptors in modulating the exocytotic release of glutamate and the
[Ca2+]i changes in the rat hippocampus. In conditions of co-activation, there appears to exist a physiological cross-talk between Y1
and Y2 and also between Y2 and Y5 receptors, in which Y2 receptors play a predominant role. Moreover, we also show that Y1
and Y2 receptors exert their inhibitory action by directly modulating L-, N-, and P-/Q-type VGCCs, whereas the inhibition of
glutamate release mediated by the Y5 receptors seems to involve P-/Q-type VGCCs.
 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Neuropeptide Y (NPY) is one of the most abundant
and widely distributed neuropeptides in both central and
peripheral nervous system (Wahlestedt and Reis, 1993).
Moreover, it is known that NPY plays an important role
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in the regulation of neuronal activity: inhibits calcium
currents (Toth et al., 1993), modulates transmitter release
in a highly selective manner (Silva et al., 2001) and
reduces hippocampal epileptiform activity in vitro and
in vivo (Colmers and Bleakman, 1994; Woldbye et al.,
1997). However, many other functions have been sug-
gested for NPY, including regulation of feeding, anxiety,
memory, cardiovascular function (Grundemar and Ha˚k-
anson, 1994), and NPY can also act as a neuroprolifer-
ative factor (Hansel et al., 2001).
Studies in which agonist fragments and analogues of
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NPY were tested indicate that at least three subtypes of
NPY receptor can be distinguished pharmacologically in
the central nervous system (Michel et al., 1998). The
NPY Y1 receptor has a high affinity for
[Leu31,Pro34]NPY, whereas Y2 binds COOH-terminal
fragments like NPY13-36 (Gerald et al., 1995). More
recently, Cabrele et al. (2000) developed the first Y5
receptor-selective analogue of NPY, [Ala31,Aib32]NPY.
Also, the non-peptide antagonist, BIBP3226, binds and
inhibits specially the Y1 receptor subtype (Wieland et
al., 1995), whereas T4-[NPY(33-36)]4 is a competitive
inhibitor of Y2 receptors (Grouzmann et al., 1995).
Recently, Doods et al. (1999) have also characterized a
more potent and selective Y2 receptor antagonist,
BIIE0246, and Kanatani et al. (2000) a new Y5 receptor
antagonist, L-152,804.
The hippocampus is particularly enriched with NPY
and NPY receptors, with high expression of Y1 receptors
in dentate gyrus, expression of Y2 receptors in all of the
other hippocampal regions and relatively high content of
mRNA for Y5-receptor throughout the CA regions and
dentate gyrus (Parker and Herzog, 1999). Indeed, the
seizure-related increase in NPY expression is
accompanied by modified levels of NPY subtypes Y1,
Y2 and Y5 in the hippocampus (Kopp et al., 1999). The
NPY Y5 receptor is the most recently discovered NPY
receptor, and has been proposed to mediate the anticon-
vulsant actions of NPY in adult rats in vivo (Woldbye
et al., 1997).
NPY is able to inhibit excitatory neurotransmission
in both slices as well as in hippocampal cell cultures
(Bleakman et al., 1992). The activation of Y2 receptors
inhibits potassium-stimulated glutamate release in hip-
pocampal slices (Greber et al., 1994), and NPY can also
reduce activity-dependent calcium increases in rat den-
tate granule cells, predominantly by activating an Y1
receptor subtype (McQuiston et al., 1996). There is evi-
dence that presynaptic inhibition produced by NPY is
associated with a reduction in Ca2+ influx caused by
selective inhibition of neuronal N-type Ca2+ channels
(Toth et al., 1993; McQuiston et al., 1996). NPY also
inhibits both N- and L-type VGCCs of frog mel-
anotrophs (Valentijn et al., 1994). Moreover, it is known
that ω-conotoxin GVIA-sensitive (N-type) and ω-aga-
toxin IVA-sensitive (P-/Q-type) calcium channels are
involved in synaptic transmission at the CA3-CA1 syn-
apse (Wu and Saggau, 1994), and unidentified types of
calcium channels, resistant to both ω-CgTx GVIA and
ω-Aga IVA, are also significantly involved in the pro-
cess of transmitter release. Indeed, activation of Y2
receptors inhibits N-type, P-/Q-type, and unidentified
presynaptic VGCC (Qian et al., 1997).
We have recently identified Y1 and Y2 receptors in
glutamatergic nerve terminals, and both receptors
inhibited the KCl-evoked release of glutamate (Silva et
al., 2001). However, the functional interplay between Y1
and Y2 receptors, and the selective role of Y5 receptors
on the modulation of glutamate release and on the [Ca2+]i
changes were never addressed. The aim of this study was
to investigate the involvement of NPY Y1, Y2 and Y5
receptors in the modulation of the exocytotic release of
glutamate and the [Ca2+]i changes in the rat hippocam-
pus. We show here a physiological cross-talk between
Y1 and Y2 receptors and also between Y2 and Y5 recep-
tors, with Y2 receptor playing a predominant role. More-
over, we could also show a direct involvement of L-,
N-, and P-/Q-type VGCCs, on the inhibitory effects
mediated by NPY receptors.
2. Methods
2.1. Materials
Neuropeptide Y, [Leu31,Pro34]neuropetide Y, neurop-
etide Y13-36, neuropeptide Y (19-23)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-Pancreatic Poly-
peptide and ω-conotoxin GVIA were obtained from
Bachem, Bubendorf, Switzerland. ω-Agatoxin IVA was
obtained from Peptide Institute, Inc., Osaka, Japan,
whereas nitrendipine was a kind gift of Dr G. Ter-
stappen, from Bayer AG, Germany. (R)-N2-
(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]
argininamide (BIBP3226) was purchased from Peninsula
Laboratories, Belmont, CA, USA, and (S)-N2-[[1-[2-[4-
[(R,S)-5,11-Dihydro-6(6h)-oxodibenz[b,e]azepin-11-yl]-
1-piperazinyl]-2-oxoethyl] cylopentyl] acetyl]-N-[2-
[1,2-dihydro-3,5(4H)-dioxo-1,2-diphenyl-3H-1,2,4-
triazol-4-yl]ethyl]-argininamid (BIIE0246) was kindly
supplied by Dr Henri Doods (Boehringer Ingelheim
Pharma KG, Germany). L-152,804 (5,5-dimethyl-2-
(2,3,4,9-tetrahydydro-3,3-dimethyl-1oxo-1H-xanthen-9-
yl)-1,3-cyclohexanedione) was obtained from Tocris,
Bristol, UK. Ionomycin was purchased from Calbi-
ochem-Boehringer, San Diego. Neurobasal medium,
B27 supplement, gentamicin and trypsin (USP grade)
were purchased from GIBCO BRL, Life Technologies,
Scotland, UK. Glutamate, DNase (DN-25) and L-glu-
tamic acid dehydrogenase type II were obtained from
Sigma Chemical, St. Louis, MO, USA. The acetoxyme-
thyl ester of Fura-2 (Fura-2/AM) and Pluronic F-127
were purchased from Molecular Probes, Leiden, The
Netherlands. All the other reagents were from Sigma
Chemical, St Louis, MO, USA or from Merck-Schuch-
ardt, Germany.
2.2. Preparation of synaptosomes
A partially purified synaptosomal fraction (P2) was
isolated from hippocampi or from hippocampal subre-
gions (CA1, CA3 and dentate gyrus) (Silva et al., 2001)
of male Wistar rats (2 month-old), essentially as
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described previously for brain cortex (McMahon et al.,
1992), with some modifications (Malva et al., 1996). The
hippocampi were homogenized in 0.32 M sucrose, 10
mM HEPES–Na, pH 7.4, and centrifuged at 3000 g for
2 min. The pellet obtained was resuspended, followed
by sedimentation at the same speed. The combined
supernatants were spun for 12 min at 14,600 g, and a P2
pellet was obtained. The upper, whiter layer of this pellet
was resuspended in the sucrose medium.
Coronal slices of the hippocampus (800 µm thick)
were prepared for the isolation of synaptosomes from
hippocampal subregions (CA1, CA3 and dentate gyrus).
In each slice, the fimbria and the subiculum were separ-
ated from the rest of each slice, under stereomicroscopic
observation. CA3 sub-slices were obtained by separation
from CA1 and dentate gyrus, and, the last separation
(CA1 from dentate gyrus) was performed through the
hippocampal sulcus. The pooled sub-slices were homo-
genized in the sucrose medium indicated above, trans-
ferred to Eppendorf tubes and centrifuged as described
for the isolation of whole hippocampal synaptosomes.
The P2 pellet of each subregion was resuspended in buff-
ered sucrose medium (Malva et al., 1996; Silva et al.,
2001). The protein concentration was determined by the
Biuret method (Layne, 1957). For glutamate release
experiments the synaptosomes were stored as drained
pellets, containing 1 mg of protein.
2.3. Cell culture
Hippocampal neurons were dissociated from hippo-
campi of E18-E19 Wistar rat embryos, after treatment
with trypsin (2.0 mg/ml, 15 min, 37 °C) and deoxyribon-
uclease I (0.20 mg/ml) in Ca2+- and Mg2+-free Hank’s
balanced salt solution (137 mM NaCl, 5.36 mM KCl,
0.44 mM KH2PO4, 0.34 mM Na2HPO4.2H2O, 4.16 mM
NaHCO3, 5 mM glucose, 1 mM sodium pyruvate, 10
mM HEPES, pH 7.4). The cells were cultured in serum-
free Neurobasal medium, supplemented with B27 sup-
plement, glutamate (25 µM), glutamine (0.5 mM) and
gentamicin (0.12 mg/ml), as described previously
(Brewer et al., 1993). Cultures were kept at 37 °C in a
humidified incubator in 5% CO2/95% air, for 7–8 days,
the time required for maturation of hippocampal neu-
rons. Cells were plated on poly-D-lysine-coated (0.1
mg/ml) glass coverslips at a density of 0.2 × 106
cells/cm2 for Fura-2 fluorescence.
2.4. Measurement of glutamate release
The release of endogenous glutamate was followed
using a continuous fluorimetric assay as previously
described (Nicholls et al., 1987), with some modifi-
cations (Malva et al., 1996). Synaptosomes (1 mg
protein) were incubated for 20 min at 37 °C in the fol-
lowing medium (in mM): 132 NaCl, 1 KCl, 1 MgCl2,
1.2 H3PO4, 0.1 CaCl2, 10 glucose, 10 HEPES-Na, pH
7.4, with 0.1% fatty acid-free bovine serum albumin
(BSA). After this period, the NPY receptor
agonists/antagonists, and/or ω-Aga IVA were added to
the incubation medium for more 10 min. Then, synapto-
somes were centrifuged at 15,800 gmax, and resuspended
in 1 ml of the same medium, without bovine serum albu-
min and with 1 mM CaCl2. The suspension was trans-
ferred to a stirred cuvette at 37 °C, followed by the
addition of 1 mM NADP+, 50 U of purified glutamate
dehydrogenase, and again NPY receptor
agonists/antagonists and/or ω-Aga IVA. Fluorescence
was measured by using a Perkin Elmer model LS-5B
luminescence spectrometer at the excitation and emis-
sion wavelengths of 340 and 460 nm, respectively, with
excitation and emission slits of 5 and 10 nm, respect-
ively. The data were collected at 0.5 s intervals and the
quantification of glutamate was performed at the end of
each experiment by adding 2.5 nmol of L-glutamate,
for calibration.
2.5. [Ca2+]i measurements
Measurement of [Ca2+]i were carried out in popu-
lations of hippocampal neurons cultured on glass
coverslips at a density of 0.2 × 106 cells/cm2. The cells
were incubated with 5 µM Fura-2/AM and 0.2% Plu-
ronic F-27 in Krebs buffer (132 mM NaCl, 1 mM KCl,
1 mM MgCl2, 100 µM CaCl2, 1.2 mM H3PO4, 10 mM
glucose and 10 mM HEPES–Na, pH 7.4) with 0.1% fatty
acid-free bovine serum albumin for 40 min at 37 °C, and
further incubated for 10 min in Krebs buffer without the
dye. When NPY receptor agonists and antagonist, ω-Aga
IVA and ω-CgTx GVIA were tested, they were present
both in the last ten minutes incubation and in reaction
medium. The coverslips were rinsed with Krebs buffer
and mounted, with a special holder (Perkin-Elmer
L2250008), in a temperature-controlled cuvette. The
fluorescence of Fura-2-loaded cells was monitored using
a computer-assisted Spex Fluoromax spectrofluorometer,
at 510 nm emission and double excitation at 340 and
380 nm, using 5 nm slits. The calibration was made in
the presence of 6 µM ionomycin (1 mM CaCl2; Rmax),
at 400 s, and 8 mM EGTA (Rmin), at 700 s.
2.6. Data analysis
The data are expressed as means ± SEM. Statistics
were performed using an analysis of variance (ANOVA),
followed by Dunnett’s or Bonferroni’s post-tests, as indi-
cated in the figure legends.
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3. Results
3.1. Modulation of glutamate release by NPY Y1, Y2
and Y5 receptors in rat hippocampal nerve terminals:
functional interaction between presynaptic NPY
receptors
Excitatory synaptic transmission in the nervous sys-
tem is mostly mediated by glutamate. Under pathological
conditions leading to massive glutamate release the hyp-
eractivation of glutamate receptors causes deregulation
of the [Ca2+]i, which activates a large number of Ca2+-
dependent processes that cause neuronal damage. We
have previously examined the modulation of glutamate
release by Y1 and Y2 receptors, and observed that these
receptors have a differential effect in the three main hip-
pocampus subregions (CA1, CA3 and dentate gyrus)
(Silva et al., 2001).
Our first experiments revealed that the endogenous
agonist, NPY (1 µM), inhibited the KCl-evoked total
glutamate release in hippocampal nerve terminals to
48.2±2.2% of the control (Fig. 1). As we showed before
(Silva et al., 2001), this inhibitory effect was insensitive
to 1 µM BIBP3226, a NPY Y1 receptor antagonist
(52.3 ± 3.7% of the control) (Fig. 1B), and was partially
prevented by the competitive antagonist of Y2 receptor,
T4-[NPY(33-36)]4 (1 µM) (72.6 ± 3.1% of the control).
However, in the present study we show that the more
selective Y2 receptor antagonist, BIIE0246 (1 µM),
completely prevents the inhibition caused by NPY
(98.6 ± 3.0% of the control) (Fig. 1B), whereas the Y5
receptor antagonist did not have a significant effect
(61.2 ± 2.3% of control). This finding indicates that Y2
receptors play a predominant role in mediating NPY-
induced inhibition of glutamate release in the hippocam-
pus.
Since NPY is able to activate all NPY receptors, we
have now pharmacologically dissected the activity of
Y1, Y2 and Y5 receptors. We observed that 1 µM
[Leu31,Pro34]NPY, 300 nM NPY13-36 or 1 µM NPY(19-
23)-(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP inhibited
the glutamate release to 71.6 ± 1.8%, 60.1 ± 2.1% or
68.2 ± 2.5% of the control, respectively (Fig. 2).
The inhibitory effect induced by Y1 receptor acti-
vation was completely abolished by 1 µM BIBP3226
(93.4 ± 2.3% of the control), but not by the Y2
(72.17 ± 1.1% of the control) or Y5 (64.5 ± 2.3% of the
control) receptor antagonist (Fig. 2). Moreover, 1 µM
BIIE0346 completely prevented the inhibition of gluta-
mate release induced by 300 nM NPY13-36
(109.7 ± 4.3% of the control), and this effect was not
altered by the Y1 (61.0 ± 2.9% of the control) or Y5
(59.8 ± 3.7% of the control) receptor antagonist (Fig. 2).
Concerning the Y5 receptor subtype, the inhibitory effect
induced by 1 µM of the agonist was not significantly
abolished by 1 µM BIIE0246 (69.2 ± 1.3% of the
Fig. 1. (A) Inhibitory effect of NPY (1 µM) on the 15 mM KCl-
evoked glutamate release in hippocampal synaptosomes (1 mM Ca2+
present in the external medium). Total glutamate release in control
conditions was 1.1 ± 0.1 nmol glutamate/mg protein/min, while in the
presence of 1 µM NPY was 0.6 ± 0.1 nmol glutamate/mg protein/min.
(B) Quantitative analysis of the effect of Y1, Y2 or Y5 receptor antag-
onists on KCl-evoked glutamate release inhibition induced by 1 µM
NPY. The synaptosomes were incubated with the NPY receptor agon-
ists or/and antagonists for 10 min before starting the measurement of
glutamate release, which was followed for 240 s after KCl depolaris-
ation. The results are expressed as mean percentage of
control ± SEM of 5–10 independent experiments, in different synapto-
somal preparations. ∗∗∗P  0.001—Dunnett’s post-test; statistical sig-
nificance when compared to the control (KCl stimulation).
control), nor by 1µM BIBP3226 (79.1 ± 1.4% of the
control), but was prevented in the presence of the Y5
receptor antagonist (95.0 ± 3.8% of the control). Fur-
thermore, the inhibition of glutamate release induced by
1 µM NPY(19-23)-(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,
Gln34)-PP was due to the activation of Y5 receptors in
the dentate gyrus and CA3 subregion of the hippocam-
pus, since the glutamate release was 55.3 ± 2.8% of the
control in the dentate gyrus and 70.8 ± 1.8% of the con-
trol in the CA3 subregion, without an effect in the CA1
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Fig. 2. Quantitative analysis of the effect of NPY Y1, Y2 and Y5
receptor agonists/antagonists on the total glutamate release evoked by
15 mM KCl depolarisation in hippocampal synaptosomes. Glutamate
release in control conditions was on average 1.1 ± 0.1 nmol
glutamate/mg protein/min. The results are expressed as mean percent-
age of control ± SEM of 5–14 independent experiments, in different
synaptosomal preparations. ∗∗∗P  0.001—Dunnett’s post-test; stat-
istical significance when compared to the control (KCl stimulation).
subregion of the hippocampus (100.3 ± 2.5% of control)
(Fig. 3).
The addition of the selective agonists for Y1 and Y2
or for Y2 and Y5 receptors did not result in a potenti-
ation of the inhibitory effect of each agonist added separ-
ately (67.6 ± 2.2% or 65.7±3.6% of the control,
respectively) (Fig. 4A,B). Moreover, the inhibition of the
glutamate release induced by the simultaneous presence
of 1 µM [Leu31,Pro34]NPY and 300 nM NPY13-36 (Fig.
4A) or 300 nM NPY13-36 and 1 µM NPY (19-23)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP (Fig. 4B)
was prevented by the blockade of only Y2 receptors with
BIIE0246 (94.0 ± 1.8% or 91.7 ± 2.2% of the control,
respectively), and not by the inhibition of Y1 or Y5
receptors with BIBP3226 (72.0±1.8% of the control)
(Fig. 4A) or L-152,804 (67.0 ± 2.7% of the control)
(Fig. 4), respectively. In contrast, the co-activation of
both Y1 and Y5 receptors resulted in a potentiation of
the inhibitory effect (52.0 ± 2.1% of the control) of each
agonist added separately (Fig. 4C). This effect was only
partially prevented by 1 µM BIBP3226 (83.5 ± 1.8% of
the control) or 1 µM L-152,804 (81.8 ± 1.3% of the
control), but the presence of both antagonists completely
blocked the inhibitory effect of the agonists
(93.3 ± 1.3% of the control) (Fig. 4C).
Fig. 3. Quantitative analysis of the effect of 1 µM NPY (19-23)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP on the total glutamate
release evoked by 15 mM KCl in synaptosomes obtained from the
whole hippocampus and from the subregions, CA1, CA3 and dentate
gyrus (DG). The results represent the mean ± SEM of 3–12 inde-
pendent experiments, in different synaptosomal preparations. ∗P 
0.05; ∗∗∗P  0.001—Dunnett’s post-test; statistical significance when
compared to the control (KCl stimulation in each subregion).
3.2. Modulation of the [Ca2+]i response by NPY Y1,
Y2 and Y5 receptor activation in hippocampal
neurons: functional interaction between NPY Y1 and
Y2 receptors
Calcium is a mediator of many physiological func-
tions, and deregulation of the [Ca2+]i leads to cell dys-
function and ultimately to cell death. Therefore, we
investigated the modulatory effect of NPY receptors on
the KCl-evoked increase in the [Ca2+]i measured in a
whole population of hippocampal neurons.
In the presence of the endogenous agonist, 1 µM
NPY, the [Ca2+]i response induced by 30 mM KCl was
significantly inhibited (79.9 ± 1.3% of the control) (Figs.
5B and 6A), and this effect was completely prevented
by the Y2 receptor antagonist, BIIE0246,
(110.7 ± 9.2% of the control), while the Y1 receptor
antagonist, BIBP3226, did not have any effect
(70.1 ± 2.8% of the control) (Fig. 6A). Moreover, the
selective activation of Y1 or Y2 receptors also resulted
in an inhibitory effect (76.9 ± 4.0% or 76.4 ± 2.8% of
the control, respectively) (Figs. 5C,D and 6A), in con-
trast to what happened in the presence of the Y5 receptor
agonist (93.4 ± 1.6% of the control), which did not
inhibit the KCl-stimulated [Ca2+]i changes (Figs. 5E
and 6A).
We further investigated the selectivity of Y1 and Y2
receptors-mediated increase in the [Ca2+]i by using Y1
and Y2 receptor antagonists. The Y1 receptor antagonist
completely prevented the inhibitory effect induced by 1
µM [Leu31,Pro34]NPY (104.5 ± 2.7% of the control)
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Fig. 4. Qualitative analysis of the effect of (A) NPY Y1 and Y2, (B) Y2 and Y5 or (C) Y1 and Y5 receptor agonists and antagonists on the total
glutamate release evoked by 15 mM KCl depolarisation in hippocampal synaptosomes. The results represent the mean ± SE.M of 3–12 independent
experiments, in different synaptosomal preparations. ∗∗∗P  0.001—Dunnett’s post-test; statistical significance when compared to the control
(KCl stimulation).
(Fig. 6A), while the Y2 receptor antagonist did not have
any significant effect (74.8 ± 4.8% of the control) (Fig.
6A). In contrast, inhibition caused by 300 nM NPY13-
36 was prevented by the selective Y2 receptor antagonist
(115.0 ± 4.7% of the control) (Fig. 6A), but was not alt-
ered by the Y1 receptor antagonist (74.9 ± 5.6% of the
control) (Fig. 6A).
As in glutamate release studies, we observed that the
addition of both selective agonists did not result in a
potentiation of the independent inhibitory effect of the
agonists added separately (79.2 ± 2.0% of the control)
(Fig. 6B). Moreover, again the inhibitory effect induced
by 1 µM [Leu31,Pro34]NPY plus 300 nM NPY13-36 was
completely prevented by the Y2 receptor antagonist
(101.1 ± 3.3% of the control) (Fig. 6B), but not by the
Y1 receptor antagonist (74.0 ± 8.0% of the control)
(Fig. 6B).
3.3. Characterization of the inhibitory effect mediated
by NPY Y1 and Y2 receptors activation
To further understand the effect of Y1 and Y2 recep-
tors activation on Ca2+ influx, we compared the effects
of VGCC blockers and NPY receptor agonists on both
the KCl-evoked [Ca2+]i increase and glutamate release.
As we shown before, 1 µM [Leu31,Pro34]NPY (Figs.
5B and 7A) or 300 nM NPY13-36 (Figs. 5C and 7B)
reduced the [Ca2+]i increase induced by 30 mM KCl to
76.9 ± 4.0% or 76.4 ± 2.8% of the control, respectively.
Co-application of 1 µM [Leu31,Pro34]NPY (Fig. 7A) or
300 nM NPY13-36 (Fig. 7B) with 1 µM nitrendipine,
an L-type VGCC inhibitor (Bean, 2001), did not further
inhibit the [Ca2+]i response to 30 mM KCl
(71.4 ± 3.9% or 72.0 ± 1.6% of the control,
respectively), as compared to the effect of either
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Fig. 5. Representative recordings showing the increase in [Ca2+]i
stimulated by 30 mM KCl in a control situation (A), and in the pres-
ence of 1 µM NPY (B), 1 µM [Leu31,Pro34]NPY (C), 300 nM NPY
13-36 (D) or 1 µM NPY (19-23)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP (E), in cultured hippocam-
pal neurons. In control conditions the basal [Ca2+]i was 51.4 ± 1.6 nM
and the KCl-evoked [Ca2+]i was 214.0 ± 8.6 nM (n  11). The cells
were incubated with the NPY receptor agonists for 10 min before start-
ing the [Ca2+]i measurements. In (B–D) is possible to observe the inhi-
bition of KCl-stimulated [Ca2+]i changes.
[Leu31,Pro34]NPY (Fig. 7A) or NPY13-36 (Fig. 7B).
Nitrendipine alone had an effect (74.7 ± 2.2% of
the control) similar to that obtained in the presence
of Y1 (Fig. 7A) or Y2 (Fig. 7B) receptor agonists,
and did not affected the basal [Ca2+]i
(110.0 ± 9.9% of the control, n  6, P  0.05, Dun-
nett’s test).
The same qualitative results were obtained in the pres-
ence of the N-type VGCC blocker ω-conotoxin GVIA
(ω-CgTx GVIA), since the simultaneous application of
this toxin and [Leu31,Pro34]NPY (Fig. 7A) or NPY13-36
(Fig. 7B) (74.3 ± 1.9% or 76.7 ± 2.7% of the control,
respectively), did not potentiate the [Ca2+]i inhibition
induced by Y1 or Y2 receptor agonists alone. Also, the
inhibitory effect induced by 500 nM ω-CgTx GVIA
(74.4 ± 2.7% of control) was similar to that obtained
with Y1 (Fig. 7A) or Y2 (Fig. 7B) receptor agonists, and
again this toxin had no significant effect on the basal
[Ca2+]i.
Contrary to what happened in the presence of nitrendi-
pine, or ω-conotoxin GVIA, the P-/Q-type VGCC
blocker ω-Aga IVA, did not show a strong inhibitory
effect by itself (88.3 ± 3.3% of control), and co-appli-
cation of [Leu31,Pro34]NPY or 300 nM NPY13-36 with
100 nM ω-Aga IVA did not further inhibited [Ca2+]i
response to 30 mM KCl, as compared to the effect of
either Y1 or Y2 receptor agonists (75.9 ± 3.9% or
78.1 ± 3.1% of control, respectively).
We showed previously that Y1 and Y2 receptors acti-
vation inhibits both Ca2+-dependent and Ca2+-inde-
pendent glutamate release (Silva et al., 2001), and we
have now investigated the pathway between NPY recep-
tor activation and the inhibition of glutamate release. For
this, we triggered the exocytotic release of glutamate
with ionomycin in the presence of Ca2+. This Ca2+ iono-
phore promotes Ca2+ influx and glutamate release inde-
Fig. 6. (A) Quantitative analysis of the effect of NPY Y1, Y2 and Y5
receptor agonists/antagonists and (B) effect of co-activation of NPY Y1
and Y2 receptors on the initial rise in [Ca2+]i stimulated by 30 mM KCl,
in cultured rat hippocampal neurons. The changes in [Ca2+]i ([Ca2+]i)
were calculated as the difference between the peak values following
depolarisation and the basal values acquired just prior to the stimulus.
The cells were incubated with the NPY receptor agonists or/and antagon-
ists for 10 min before starting the [Ca2+]i measurements. The results are
expressed as mean percentage of control ± SEM of 5–13 independent
experiments. ∗∗∗P  0.001—Dunnett’s post-test; statistical significance
when compared to the control (KCl stimulation).
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Fig. 7. Comparison of the inhibitory effects of Y1 (A) or Y2 (B)
receptor agonists and of Ca2+ channel blockers ω-Conotoxin GVIA (ω-
CgTx, 500 nM), ω-Agatoxin IVA (ω-Aga, 100 nM) or nitrendipine
(Nit, 1 µM) on the [Ca2+]i increase stimulated by 30 mM KCl, in
cultured hippocampal neurons. The cells were incubated with the Ca2+
channels blockers and the NPY receptor agonists for 10 min before
starting the [Ca2+]i measurements. In control conditions the basal
[Ca2+]i was 51.4 ± 1.6 nM and the KCl-evoked [Ca2+]i was
214.0 ± 8.6 nM. The results are expressed as mean percentage of
control ± SEM of 6–9 independent experiments. ∗P  0.05—Bonfer-
roni’s post-test; statistical significance when compared to the effect of
[Leu31,Pro34]NPY (A) or NPY13-36 (B) alone.
pendently of VGCC activity. We observed that none of
the NPY receptor agonists was able to reduce the iono-
mycin-stimulated glutamate release (Fig. 8), in contrast
to what happened when we stimulated glutamate release
with KCl (Figs. 1B and 2).
We have also used nerve terminals to investigate
whether Y1, Y2 or Y5 receptor activation inhibit gluta-
mate release by blocking P-/Q-type channels, the pre-
dominant VGCC at the nerve terminals. In the presence
of 100 nM ω-Aga IVA, the total glutamate release was
inhibited to 52.9 ± 3.0% of the control (Fig. 9). More-
over, co-application of [Leu31,Pro34]NPY, 300 nM
NPY13-36 or 1 µM NPY (19-23)-
(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-PP with 100 nM
ω-Aga IVA did not further inhibited the glutamate
release in response to 15 mM KCl, as compared to the
effect of ω-Aga IVA by itself (48.9 ± 1.1%,
50.5 ± 1.9% or 41.2 ± 2.6% of control, respectively)
(Fig. 9).
4. Discussion
Our results suggest that the selective co-activation of
both NPY Y1 and Y2 or Y2 and Y5 receptors inhibits
the activity of Y1 or Y5 receptors, respectively, by an
undetermined mechanism. Moreover, we also show that
the inhibitory mechanism triggered by NPY receptor
activation involves the activity of VGCCs.
Fig. 8. Lack of effect of NPY and Y1, Y2 and Y5 receptor agonists
on the glutamate release evoked by 5 µM ionomycin, in rat hippocam-
pal synaptosomes. The synaptosomes were incubated with the NPY
receptor agonists for 10 min before starting the measurement of gluta-
mate release. Total glutamate release in control conditions was
1.0 ± 0.02 nmol glutamate/mg protein/min The results are expressed
as mean percentage of control ± SEM of 7–14 independent experi-
ments, in different synaptosomal preparations.
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Fig. 9. Comparison of the inhibitory effects of Y1, Y2 or Y5 receptor
agonists and Ca2+ channel blocker ω-Agatoxin IVA (ω-Aga, 100 nM)
on the total glutamate release stimulated by 15 mM KCl, in rat hippo-
campal synaptosomes. The synaptosomes were incubated with ω-Aga
IVA and the NPY receptor agonists for 10 min before starting the
measurement of glutamate release. Glutamate release in control con-
ditions was on average 1.1 ± 0.1 nmol glutamate/mg protein/min. ∗∗∗
P  0.001—Dunnett’s post-test; statistical significance when com-
pared to the control (KCl stimulation).
Presynaptic inhibition induced by NPY is mostly
mediated by Y2 receptors (Colmers et al., 1991). Indeed,
in the adult rat hippocampus, the inhibitory effect of
NPY on glutamate-mediated excitatory transmission
appears to be mediated by presynaptic Y2 receptors,
possibly by reducing Ca2+ influx through N-type Ca2+
channels (Bleakman et al., 1992; Klapstein and Colmers,
1992). However, Y1 receptors play also a critical role
in the rat hippocampus. McQuiston et al. (1996) demon-
strated that NPY inhibits an N-type ICa in rat dentate
granule cells by activating Y1 receptors. Accordingly,
we also determined that Y1 and Y2 receptors play an
important role in the modulation of glutamate release,
since when selectively activated they both inhibit Ca2+-
dependent glutamate release in hippocampal nerve ter-
minals (Silva et al., 2001). However, the Y2 receptor
subtype seems to play a predominant role in synaptic
excitation when activated by the endogenous agonist,
NPY, (McQuiston and Colmers, 1996), which is in
agreement with the present results. Indeed, we show here
that the Y1 or Y5 receptor antagonists did not prevent
the inhibition of glutamate release induced by NPY. This
effect is not due to the absence of functional Y1 and Y5
receptors since, in the presence of [Leu31,Pro34]NPY or
NPY (19-23)-(Gly1,Ser3,Gln4,Thr6,Ala31,Aib32,Gln34)-
PP, we observed a significant inhibition of the glutamate
release. Therefore, in spite of the presence of the three
receptors in hippocampal nerve terminals, the endogen-
ous agonist, NPY, inhibits glutamate release by activat-
ing Y2 receptors instead of Y1 and Y5 receptors.
We also show in this study that Y5 receptor activation
inhibits glutamate release in hippocampal nerve ter-
minals, and that this effect is due to the activation of
Y5 receptors in dentate gyrus and CA3 subregion of the
hippocampus. These results are in agreement with the
idea that Y5 receptors play an important role in the con-
trol of the glutamatergic mechanism in the hippocampus,
and that Y5-like receptors inhibit kainic acid seizures
(Woldbye et al., 1997; Marsh et al., 1999). Recently,
Guo et al. (2002) also showed that Y5 receptor subtype
plays a critical role in modulation of hippocampal excit-
atory transmission at the hilar-to-CA3 synapse in the
mouse.
Using hippocampal neurons in culture, we also
observed that Y1 and Y2 receptors inhibited KCl-evoked
[Ca2+]i changes in a very selective way, in contrast to
what happened in the presence of the Y5 receptor agon-
ist, which failed to significantly modulated the [Ca2+]i
changes. Moreover, as we showed in the glutamate
release studies, the inhibitory effect induced by NPY is
also mediated by Y2 receptors. Thus, if these three NPY
receptors subtypes (Y1, Y2 and Y5) coexist in the hippo-
campus, and have an important role in mediating neu-
ronal excitability, it is critical to understand the putative
functional interaction between different NPY receptors
when selectively and simultaneously activated.
In the presence of both selective agonists for Y1 and
Y2 or Y2 and Y5 receptors, we did not observe a
potentiation of the inhibitory effect when compared to
the independent inhibition induced by each agonist, in
glutamate release or [Ca2+]i changes studies. This obser-
vation is in agreement with the co-expression of different
NPY receptors in the same glutamatergic terminals of
the dentate gyrus and CA3 subregion. In a previous
study we showed that the selective activation of Y1
receptors in the CA1 subregion of the hippocampus did
not inhibit the KCl-evoked glutamate release (Silva et
al., 2001), and in the present study we show the same
effect for the Y5 receptor. Moreover, the inhibition of
glutamate release and [Ca2+]i changes induced by
[Leu31,Pro34]NPY plus NPY13-36 was sensitive only to
the presence of the Y2 receptor antagonist. Also, the
inhibition of glutamate release induced by the co-acti-
vation of both Y2 and Y5 receptors was only prevented
by the Y2 receptor antagonist. Surprisingly, the same
was not observed when the Y1 and Y5 receptors were
simultaneously activated. Therefore, it seems that Y2 is
functionally coupled to Y1 and Y5 receptors, and when
Y2 receptors are activated the Y1 and Y5 receptors
stay ‘silent’.
Functional interaction between different metabotropic
receptors has been described (Bouvier, 2001). Oligomer-
ization of GABAB receptors (Marshall et al., 1999), som-
atostatin receptors (Rocheville et al., 2000), opioid
291A.P. Silva et al. / Neuropharmacology 44 (2003) 282–292
receptors (Jordan and Devi, 1999), and even oligomeriz-
ation of metabotropic receptors for different neuro-
transmitters like β-adrenergic and opioid (Jordan et al.,
2001) can profoundly affect the expected pharmacology
of each receptor individually (Bouvier, 2001). The
presently described interaction between Y1 and Y2 or
Y2 and Y5 receptors suggest the formation of oligomers
of Y1 and Y2 or Y2 and Y5 receptors, and the activation
of such a complex would predominantly activate the
NPY Y2 receptors over Y1 and Y5 receptors.
In the present study we also show that the inhibitory
effect induced by Y1 or Y2 receptors in [Ca2+]i changes
is mainly due to the inhibition of N- and L-type, in both
cases. Since in this work we measured the [Ca2+]i
changes in the whole cell, these results are compatible
with the presence of Y1 receptors in the cell body, den-
drites and in the nerve terminal, which is in agreement
with the pre- and post-synaptic localization of these
receptors (Silva et al., 2001). Concerning the results that
we obtained for the Y2 receptors, the inhibition of
[Ca2+]i changes through L-type VGCCs, may suggest the
presence of these receptors in dendrites. We also used
nerve terminals to better understand the involvement of
Ca2+ channels on the glutamate release inhibition
induced by presynaptic Y1, Y2 and Y5 receptors. We
firstly observed that the inhibitory effect induced by
NPY receptors was mediated by VGCCs, and then that
the P-/Q-type channels are clearly involved in the inhi-
bition of glutamate release. So, these results strongly
suggest the involvement of L-, N- and P-/Q-type chan-
nels in the inhibition of [Ca2+]i changes and glutamate
release mediated by NPY receptors in the hippocampus.
In agreement, other studies in rat dentate granule cells
also show that NPY inhibited Ca2+ currents mainly via
Y1 receptors, inhibiting an N-type calcium channel
(McQuiston et al., 1996). However, presynaptic Y2
receptors activation by NPY also inhibits N-type, P-/Q-
type and unidentified presynaptic VGCCs (Qian et al.,
1997), or even L-type VGCCs can be involved in the
inhibitory effects mediated by NPY (Valentijn et al.,
1994).
The cross-talk between Y1, Y2 and Y5 receptors,
described for the first time in this study, allow us to bet-
ter understand the functional interaction and the role of
each NPY receptor in the hippocampus. Since these
receptors play an important role in regulating excitatory
neurotransmission under physiological and pathological
conditions, these results may be of particular interest for
future studies concerning the anticonvulsant properties
of NPY receptors.
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